Ocera Therapeutics (OCRX) Stock: Gaining Big On Pre-Clinical Data


Ocera Therapeutics Inc (NASDAQ: OCRX)

Ocera Therapeutics is having an overwhelmingly strong time in the pre-market hours today, and for good reason. The company announced the presentation of key clinical data, exciting investors and leading to incredible gains on the stock. Of course, our partners at Trade Ideas were the first to inform us of the gains. At the moment (8:13), OCRX is trading at $1.69 per share after a gain of $0.50 per share or 42.02% thus far today.

OCRX To Present Clinical Data

As mentioned above, OCRX is having an incredible morning in the market this morning after the company announced that it will be presenting clinical data. The data will be presented at The International Liver Congress(TM) 2017. the data will be coming from the study of omithine phenylacetate. The study that the data came from investigated the effect of OCR-002 in a NAFLD rat model . The rat models showed a significant reduction in the progress of fibrosis compared to untreated NAFLD rats. The treatment also showed to reduce liver/body weight ratio, hepatic lipid content, and hepatic collagen. In a statement, Stan Bukofzer, M.D., CMO at OCRX had the following to offer…

We are again excited to see evidence of OCR-002’s ability to target ammonia in hyperammonemia-related indications that in turn drives clinical improvement… In our recently completed STOP-HE Phase 2b study in patients hospitalized with acute heptic encephalopathy (HE), OCR-002 demonstrated a highly statistically significant correlation between rapid reduction of neurotoxin ammonia, and improved in the neurocognitive symptoms of HE (p=0.0006). The preclinical study to be presented at EASL demonstrated the impact of OCR-002 in a NAFLD model and its corresponding ability to significantly reduce progression of fibrosis, adding to our belief that OCR-002 may have broad potential to treat ammonia-driven complications.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on OCRX. In particular, we’re watching the development of OCR-002. While the treatment is still in pre-clinical phase, it looks overwhelmingly promising. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we even have the time to write the story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

[Image Courtesy of Wikimedia]


Please enter your comment!
Please enter your name here